Stockscreener 앱 받기
8.82
0.63%
0.055
시간 외 거래:
8.85
0.03
+0.34%
전일 마감가:
$8.765
열려 있는:
$8.87
하루 거래량:
1.66M
Relative Volume:
0.92
시가총액:
$1.49B
수익:
$68.56M
순이익/손실:
$-437.99M
주가수익비율:
-2.7877
EPS:
-3.1639
순현금흐름:
$-396.61M
1주 성능:
+1.85%
1개월 성능:
-13.95%
6개월 성능:
+22.67%
1년 성능:
+102.76%
1일 변동 폭
$8.75
$9.03
1주일 범위
$8.545
$9.699
52주 변동 폭
$4.155
$11.66
비르 바이오테크 Stock (VIR) Company Profile
명칭
Vir Biotechnology Inc
전화
415-906-4324
주소
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
8.82 | 1.48B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
비르 바이오테크 Stock (VIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | 개시 | Evercore ISI | Outperform |
| 2025-08-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-03-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-02-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 개시 | SVB Leerink | Outperform |
| 2022-09-09 | 개시 | Morgan Stanley | Underweight |
| 2022-03-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-01-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-09-14 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-11 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 개시 | Needham | Buy |
| 2020-03-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-02-27 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 개시 | Robert W. Baird | Neutral |
| 2019-11-05 | 개시 | Barclays | Overweight |
| 2019-11-05 | 개시 | Cowen | Outperform |
| 2019-11-05 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | JP Morgan | Overweight |
모두보기
비르 바이오테크 주식(VIR)의 최신 뉴스
Eversept Partners LP Takes $2.24 Million Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Empyrean Capital Partners LP Invests $4.73 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Avoiding Lag: Real-Time Signals in (VIR) Movement - Stock Traders Daily
Vir Biotechnology, Inc. Revenue Breakdown – NASDAQ:VIR - TradingView
Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer - Moomoo
Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Vir Biotechnology Names Brent Sabatini Interim Finance Chief - The Globe and Mail
Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Vir Biotechnology Inc (VIR) Income Statement - TradingKey
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
VIR|Vir Biotechnology Inc|Price:8.800|Chg%:+0.110 - TradingKey
Vir Biotechnology Inc (VIR) Cash Flow - TradingKey
Vir Biotechnology Appoints Interim CFO Amid Transition - Intellectia AI
Vir Biotechnology Inc (VIR) Institutional Confidence - TradingKey
Vir Biotechnology Inc (VIR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vir Biotechnology Inc (VIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vir Biotechnology Inc (VIR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vir Biotechnology Inc (VIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vir Biotechnology Inc (VIR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vir Biotechnology (VIR) Appoints Interim Financial Officer Amid Leadership Changes - GuruFocus
Vir Biotechnology Inc (VIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vir Biotechnology Inc (VIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vir Biotechnology Inc (VIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vir Biotechnology Inc (VIR) Balance Sheet - TradingKey
VIR|Vir Biotechnology Inc|Price:8.690|Chg%:-0.650 - TradingKey
Vir Biotechnology: Sabatini Has Served as Senior Vice Pres and Chief Acctg Officer Since Feb 2023 >VIR - Moomoo
Why is Vir Biotechnology stock sliding today? - Investing.com
Why is Vir Biotechnology stock sliding today? By Investing.com - Investing.com Canada
Vir Biotechnology (VIR) Announces New Interim Financial Leadersh - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Shares Gap DownWhat's Next? - MarketBeat
Vir Biotechnology stock falls as CFO O’Byrne departs By Investing.com - Investing.com India
Vir Biotechnology stock falls as CFO O’Byrne departs - Investing.com
Vir Biotechnology Announces Chief Financial Officer Transition - BioSpace
Vir Biotechnology, Inc. Announces Resignation of Jason O'Byrne as Executive Vice President, Effective August 3, 2026 - marketscreener.com
Vir Biotechnology Appoints Brent Sabatini as Interim CFO Following Jason O'Byrne's Resignation - Kalkine Media
Vir Biotechnology names interim finance chief - Investing.com
Vir Biotechnology (VIR) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Vir Biotechnology Financial Chief to Depart - Moomoo
Vir Biotechnology names interim finance chief By Investing.com - Investing.com Canada
Vir Biotechnology (VIR) Short Interest & Short Float | Updated Jul 2026 $VIR - MarketBeat
VIR Q2'26 Earnings: revenue estimate is 135.88M USD - TradingView
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results - BioSpace
Vir Biotechnology to host conference call for Q2 2026 results - scanx.trade
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vir Biotechnology (VIR) Bank of America Global Healthcare Conference 2026 Summary - Quartr
VIR stock reacts to latest clinical updates and cash position - Ad-hoc-news.de
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Vir Biotechnology nears key trial results in he... - Pluang
Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead (NASDAQ:VIR) - Seeking Alpha
비르 바이오테크 (VIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
비르 바이오테크 주식 (VIR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Napolitano Janet | Director |
Jun 01 '26 |
Sale |
9.45 |
3,200 |
30,240 |
21,216 |
| Sabatini Brent | SVP, Chief Accounting Officer |
Jun 01 '26 |
Sale |
9.45 |
379 |
3,582 |
61,902 |
1.84%
0.86%
자본화:
|
볼륨(24시간):